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Abstract
The concept of autoinflammatory disease as a new disease classification has resulted in a paradigm
shift in our understanding of the the broad spectrum of immunological diseases. The effectiveness of
interleukin-1 blockade in a variety of disorders has resulted in a marked reduction in suffering for
many of these patients.
Introduction and context
Over the past 10 years a group of monogenic diseases,
termed the hereditary periodic fever syndromes (HPFS),
which present with recurrent inflammation and unex-
plained fevers as part of their phenotype, have been
classified as autoinflammatory in nature, residing at
the extreme of the immunological disease continuum
proposed in 2006 [1]. The HPFS typically manifest in the
paediatric population. There has been remarkable pro-
gress in delineation of the genetic pathways involved and
successful management of these syndromes. These
conditions are linked at the functional level, as the
reported mutations are manifested in cells and proteins
of the innate immune system. There are at least five
HPFS, which include two autosomal recessive condi-
tions, familial Mediterranean fever (FMF) and hyperim-
munoglobulinemia D with periodic fever syndrome
(HIDS), in addition to a group of autosomal dominant
diseases, including tumor necrosis factor receptor-
associated periodic syndrome (TRAPS), pyogenic arthritis,
pyoderma gangrenosum, and acne (PAPA) syndrome, as
well as three related conditions, collectively termed the
cryopyrin-associated periodic syndromes (CAPS). Familial
cold autoinflammatory syndrome (FCAS), Muckle-Wells
syndrome, and neonatal onset multisystem inflammatory
disease/chronic infantile neurologic, cutaneous, and arti-
cular syndrome (NOMID/CINCA) are all included in the
CAPS group. The genes responsible for all these auto-
inflammatory HPFS have been identified, and include
MEFV (encodingpyrin) responsible for FMF,TNFRSF1A for
TRAPS, mevalonate kinase for HIDS, CIAS1/NLRP3
for CAPS, and the PSTPIP1 gene responsible for PAPA
syndrome. These are relatively rare diseases but are asso-
ciated with increased mortality and morbidity due to an
increased potential for development of amyloidosis and
other complications [2].
The wider spectrum of autoinflammatory disease includes
polygenic conditionswithapredominantly innate immune
component, such as Crohn’s disease [2], as well as those
major histocompatibility complex class I-associated condi-
tions, including psoriasis, ankylosing spondylitis, reactive
arthritis, and Behçet’s disease, that are considered as
intermediate diseases in the immunological disease
continuum [1]. These conditions all show strong clinical
overlap.
Recent advances
The NLRP3 mutations cause spontaneous activation of
the inflammasome complex, leading to excessive inter-
leukin (IL)-1b secretion (Figure 1). This excessive
secretion is responsible for the clinical manifestations
of CAPS, as well as playing a role in a number of other
autoinflammatory diseases, including FMF and TRAPS.
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In vitro and murine studies have shown that the B30.2
domain of pyrin interacts directly with caspase-1 to
modulate IL-1b production, resulting in high levels of
IL-1b [3].
Until recently the mainstay of treatment for CAPS has
been anakinra, a recombinant non-glycosylated human
IL-1R antagonist, which blocks IL-1b from binding to its
receptor with remarkable efficacy [4]. Two alternative
IL-1 antagonists are now available. Studies have shown
that rilonacept, which acts as a soluble decoy receptor for
both IL-1b and IL-1a, can produce rapid symptomatic
improvement [5]. A fully humanised monoclonal anti-
body against IL-1b, canakinumab, has also been
approved for use in FCAS and Muckle-Wells syndrome.
A published phase III clinical study demonstrated that
canakinumab was effective in CAPS patients, with 34 of
35 patients achieving a complete clinical response within
15 days [6].
A pilot study has shown that IL-1b inhibition by
anakinra is also effective in both acute gout [7] and
resistant pseudogout [8]. Following on from this
success, a proof-of-concept study of rilonacept was
conducted in 10 patients with chronic gout; this was the
first controlled and blinded study of an IL-1 blocking
agent in this condition [9]. Rilonacept has the advan-
tage of a long plasma half-life and the ability to bind to
IL-1b with high affinity [10]; it also binds to both IL-1a
and the IL-1 receptor antagonist (IL-1ra) but with less
affinity [11].
Treatment of the autoinflammatroy disorder TRAPS is
also moving towards targeted IL-1b. Therapy had
traditionally involved corticosteroids, to which the
fever is particularly responsive [12], and then progressed
onto anti-tumour necrosis factor (anti-TNF) agents,
which have been used with varying degrees of success.
Etanercept, a recombinant human TNFR2-Fc fusion
protein, has demonstrated good efficacy [13] whereas
the monoclonal anti-TNF antibody infliximab may
induce a paradoxical inflammatory reaction and should
be avoided in suspected cases of TRAPS [14,15]. More
recently, anakinra has been used to treat TRAPS patients
[16], with one study demonstrating a prompt response
in all patients, with normalisation of acute phase
reactant levels [17].
A novel neonatal autoinflammatory disease, deficiency of
IL-1ra (DIRA), has recently been described, caused by
recessivemutations in the IL-1 receptor gene (IL1RN) with
heterozygous carriers being asymptomatic [18,19]. These
mutations, identified by two separate groups, result in a
truncated protein that is not secreted, causing cells to be
hyper-responsive to IL-1b stimulation. Disease manifesta-
tions include multifocal osteomyelitis, periostitis, and
pustulosis; the condition can be fatal but surviving
children have been treated successfully with anakinra,
resulting in a rapid reduction of the skin eruptions and
inflammation, along with regression of the bone abnorm-
alities. These studies suggest that treating DIRA patients
promptly with IL-1ramay prevent development of painful
and debilitaing bone abnormalities [18].
Figure 1. Activation of the NLRP3 inflammasome leads to
cleavage of pro-IL-1b, by caspase-1, into the mature IL-1b
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Activation usually occurs through stimulation with microbial peptides, such
as peptidoglycan (PGN), monosodium urate (MSU), and other pathogen-
associated molecular patterns (PAMP). These PAMP are recognised by the
leucine-rich repeat domain (LRR) of NLRP3. Mutations in the NACHT
domain of NLRP3 cause spontaneous activation of the this multimeric
protein complex, which leads to over-production of IL-1b. This excessive
secretion of IL-1b is mainly responsible for the clinical manifestations of the
cryopyrinopathies (CAPS) and plays a role in all periodic fevers. Screening
for mutations in the NACHT domain of NLRP3 is routinely carried out for
diagnosis of CAPS; however mutations are only found in around 50% of
cases. ASC, apoptosis-associated speck-like protein containing a CARD;
bZIP, basic leucine zipper; CARD, caspase recruitment domain; CC, coiled
coil; FIIND, function to find domain; MDP, muramyl dipeptide; PYD, pyrin
domain; SPRY, spIA/ryanodine receptor domain.
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A subset of systemic onset juvenile idiopathic arthritis
(SoJIA) has been classified as an autoinflammatory
disease in recent years. A leukocyte gene expression
study of SoJIA patients identified a unique IL-1b
signature when compared to controls, and this signature
changed significantly in patients undergoing IL-1b
blockade [20]. However, subsequent studies have failed
to replicate the IL-1b signature [21] and excessive IL-1b
secretion was not found in SoJIA patients at any stage of
therapy in one report [22]. Other potential markers of
SoJIA have also been reported; serum levels of the
myeloid-related proteins 8 and 14 (MRP-8 and MRP-14)
were significantly higher in SoJIA patients than in
healthy or other disease controls [23]. Apart from IL-1
blockade, treatment with the anti-IL-6 receptor mono-
clonal antibody tocilizumab has also proved to be
effective in SoJIA patients [24], providing another
promising therapeutic avenue in this previously difficult
to manage disorder.
In the wider disease spectrum, genes with functions in
the innate immune system have also been identified as
conferring risk to Crohn’s disease, thereby supporting an
autoinflammatory component in the pathogenesis. The
susceptibility genes include two autophagy genes,
ATG16L1 [25] and IRGM [26], and a regulatory region
downstream of NLRP3 [27]. Autophagy is linked to
innate immunity by delivery of microbial degradation
products to intracellular pathogen recognition receptors
[28]. TNF blockade is the treatment of choice in Crohn’s
disease, but IL-1b blockade is ineffective andmay aggravate
the condition [29].
Implications for clinical practice
The increased clinical awareness of autoinflammatory
disease and the remarkable effectiveness of IL-1 blockade
have raised a number of questions aboutwhich compound
(short, intermediate, or long acting) to use in a variety of
these disorders, and how early to intervene in the course of
disease in order to prevent the development of skeletal and
central nervous system defects in conditions such as CAPS
and DIRA. It is possible that prophylactic IL-1 inhibition
will be employed in the future to avoid long-term sequelae
after positive screening for these conditions.
Sustained IL-1 suppression may have potentially serious
long-term effects, which are currently unknown. Further-
more, biologics-based therapies are expensive and not
readily available for all patients who might benefit; for
example, IL-1b inhibition is not in routineuse for gout but
may have a therapeutic advantage over hypouricaemic
therapies in more severe cases. Encouraging results have
been obtained from the use of small molecules, such as
caspase-1 inhibitors, as an alternative approach to
biologics-based therapies. The orally available pro-drug
VX-765, a potent, selective inhibitor of caspase-1, blocked
IL-1b secretion in peripheral blood mononuclear cells
from FCAS patients and this may represent a future
therapeutic option [30].
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